RNS Number : 9987L
ValiRx PLC
25 April 2018





("ValiRx", the "Company" or the "Group")






London, UK., 25 April 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the European Union patent and trademark office ("EPO") has granted the EU Patent Application No. 08717866.1 ("Anti-Androgen Peptides and Uses Thereof in Cancer Therapy") covering ValiRx's lead therapeutic compound, VAL201, which is in clinical trials.  This European Union grant pleasingly follows in rapid succession to the Company's recent receipt of a US Patent grant announced on 20 March 2018.


The EPO patent application covers the molecule and use of compounds in pharmaceutically acceptable products and it applies in the following territories: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action. Furthermore, the protection sought includes therapeutic formulations with associated delivery systems.


The grant of this EU patent for VAL201 represents another major milestone in the Company's commercial strategy, since ValiRx now has substantial patent protection across the globe.  With the Company now having patent protection in all major markets, it is well positioned to benefit from the pharmaceutical industry's increasing search for novel proprietary therapies in the oncology arena.


The table below provides details of patents in the VAL201 portfolio that have been fully granted. 



Patent number

Date Filed


United States

US 14/575065

14 March 2008



EP 08717866.1

14 March 2008



JP 2009-553162

14 March 2008



AU 2008228274

14 March 2008


United Kingdom

GB 1118831.5

01 November 2011


There are patent applications currently pending in many other territories and covering various aspects of the programme.


As announced on 18 December 2017, the compound is currently in a Phase I/II study primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.  No dose limiting toxicity has been observed, nor have there been any therapeutically-related side effects (Serious Adverse Events).  


So far VAL201 has met and exceeds the predicted safety and tolerability criteria set for the trial.  Subjects have shown preliminary therapeutic efficacy and significant changes in their PSA levels related to treatment with VAL201.  These are in line with pre-clinical studies, which have shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone induced abnormal cell growth in women.


Dr Satu Vainikka, CEO of ValiRx, commented: "I am very pleased that VAL201 has received its European Union patent grant, hot on the heels of our receipt of a US patent grant.  This latest grant now means that ValiRx has substantive patent protection stretching across the globe and I believe it further bolsters the Company's opportunity of securing a partnering deal, particularly in the light of the expansion of the VAL201 trial to more speedily reach VAL201's full therapeutic potential and potential anti-cancer impact".


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


*** ENDS ***


For more information, please contact:

ValiRx plc

Tel: +44 (0) 20 3008 4416

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Richard Nash

Tel: +44 (0) 20 7213 0880

Novum Securities Limited (Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400




Notes for Editors


About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.


The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.


ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 


Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.


The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.



This information is provided by RNS
The company news service from the London Stock Exchange